Prime Medicine
Duncan Hathaway is a highly experienced professional in quality assurance and manufacturing operations, with a career spanning various reputable companies. Currently serving as Senior Manager of External QA at Prime Medicine, Inc. since March 2023, Duncan previously held roles at TCR² Therapeutics Inc. managing QA activities for cell therapy technology transfers and developing automated tracking dashboards. Prior experience includes quality management at Takeda, overseeing supplier quality agreements and leading global change notification programs. Duncan began his career at Shire, where notable roles included Quality Supervisor and Operations Development Program Associate. Educational credentials include a Bachelor of Science in Biomedical/Medical Engineering from the Georgia Institute of Technology.
This person is not in any teams
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.